Zhang, P., Sun, T., Zhang, Q., Yuan, Z., Jiang, Z., Wang, X. J., Cui, S., Teng, Y., Hu, X., Yang, J., Pan, H., Tong, Z., Li, H., Yao, Q., Wang, Y., Yin, Y., Sun, P., Zheng, H., Cheng, J., Lu, J., Zhang, B., Geng, C., Liu, J., Peng, R., Yan, M., Zhang, S., Huang, J., Tang, L., Qiu, R., Xu, B., & , (n.d.). utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet oncology, 18(3), 371–383. http://access.bl.uk/ark:/81055/vdc_100045017841.0x000012